Multiple myeloma is a formidable disease. Even with advanced treatments like CAR T-cell therapy, patients often experience a return of the disease. This is a huge problem. Scientists have been investigating why this happens. They looked at 10 patients who relapsed after receiving GPRC5D CAR T-cell therapy.

They found that eight out of ten patients had lost the GPRC5D target. This is a big deal. In three cases, genetic changes were the cause. One patient had a complete loss of the GPRC5D gene. Another had issues in the gene's regulatory regions. The third patient had losses in both GPRC5D and another gene, TNFRSF17, after trying two different CAR T-cell therapies. The rest of the patients didn't have these genetic changes, but they did have something else: lots of hypermethylation in the GPRC5D gene's regulatory regions. This means the gene was turned off, not lost.

The study also looked at MM cell lines. They found that when GPRC5D is turned off, it's often because of too much methylation. There is a drug called azacitidine that can turn GPRC5D back on in these cells. This could be a game-changer for patients who relapse.

This is a complex puzzle. Relapse after GPRC5D CAR T-cell therapy isn't just about losing the GPRC5D gene. It's also about how the gene is controlled. Understanding this could help doctors find new ways to treat MM and maybe even prevent relapse. It's a complex puzzle, but every piece we find brings us one step closer to a cure.

The Hidden Battle: Why Multiple Myeloma Comes Back

Actions